| Literature DB >> 27490093 |
Woochang Hwang1,2, Jaejoon Choi1, Mijin Kwon1, Doheon Lee3,4.
Abstract
BACKGROUND: It is necessary to evaluate the efficacy of individual drugs on patients to realize personalized medicine. Testing drugs on patients in clinical trial is the only way to evaluate the efficacy of drugs. The approach is labour intensive and requires overwhelming costs and a number of experiments. Therefore, preclinical model system has been intensively investigated for predicting the efficacy of drugs. Current computational drug sensitivity prediction approaches use general biological network modules as their prediction features. Therefore, they miss indirect effectors or the effects from tissue-specific interactions.Entities:
Mesh:
Year: 2016 PMID: 27490093 PMCID: PMC4965733 DOI: 10.1186/s12859-016-1078-6
Source DB: PubMed Journal: BMC Bioinformatics ISSN: 1471-2105 Impact factor: 3.169
Fig. 1The difference of drug response. The difference of activated pathway can change the drug response
Fig. 2System overview. 1. We constructed the backbone network. 2. We made cell line-specific networks using gene expression data of cell lines from NCI60 and the backbone network. 3. We identified cell line-specific function modules applying network clustering algorithm on the cell line specific network. 4. We identified context-specific functions by calculating module similarity of each functional module. 5. We assigned cell line-specific functional modules on cell line-specific functions to make learning models for predicting the efficacy of drugs. 6. We predicted the efficacy of drugs
Fig. 3Function vector. Function vectors are vectors containing enriched GO terms of functional modules
Fig. 4Mapping a function module to a function vector. Functional module 1 mapped on a function vector 2
Fig. 5The number of condition specific functional modules of cell lines
Context-specific function vectors
| Function | GO ID | GO description |
|---|---|---|
| 1 | GO:0000377 | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile |
| GO:0000375 | RNA splicing, via transesterification reactions | |
| GO:0006139 | Nucleobase, nucleoside, nucleotide and nucleic acid metabolic process | |
| GO:0006396 | RNA processing | |
| GO:0000398 | Nuclear mRNA splicing, via spliceosome | |
| GO:0016070 | RNA metabolic process | |
| GO:0044260 | Cellular macromolecule metabolic process | |
| 305 | GO:0002520 | Immune system development |
| GO:0002329 | Pre-B cell differentiation | |
| GO:0030097 | Hemopoiesis | |
| GO:0048534 | Hemopoietic or lymphoid organ development | |
| GO:0002327 | Immature B cell differentiation | |
| 472 | GO:0051056 | Regulation of small GTPase mediated signal transduction |
| GO:0050790 | Regulation of catalytic activity | |
| GO:0043087 | Regulation of GTPase activity |
Fig. 6Performance comparison of our model with elastic net. a Prediction performance of leave-one-out cross-validation (LOOCV) in the NCI60, as quantified by the concordance index between the predicted and observed GI50 values. b Comparison of the average concordance index of 29 drugs. c Pearson correlation coefficients between the prediction and the observed data are calculated for each algorithm. The correlation coefficients from elastic net (x-axis) are compared to those from our model (y-axis). Each dot represents prediction performance for GI50 value of one drug